Related Experiment Video

Updated: Jun 26, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

MicroRNAs and cancer: current state and future perspectives in urologic oncology

Annika Schaefer1, Monika Jung, Glen Kristiansen

  • 1Department of Urology, University Hospital Charité, Berlin, Germany.

Urologic Oncology
|January 2, 2009
PubMed

Insights

MicroRNAs (miRNAs) are small RNAs crucial in cellular processes and cancer. While vital biomarkers and therapeutic targets in oncology, their role in urologic oncology requires further intensive study due to limited current data.

Area of Science:

  • Molecular Biology
  • Oncology
  • Urology

Background:

  • MicroRNAs (miRNAs) are small non-coding RNAs regulating cellular functions.
  • miRNAs are implicated in cancer development and progression.
  • Their clinical potential as biomarkers and therapeutics is recognized in general oncology.

Purpose of the Study:

  • To review miRNA biogenesis, function, and role in tumorigenesis.
  • To explore the clinical potential of miRNAs in urologic oncology.
  • To highlight the current state of research and future directions in this field.

Main Methods:

  • A PubMed search was conducted using MeSH terms for miRNAs and urological cancers.
  • The search was limited to publications up to August 2008.
  • Included urological carcinomas of the kidney, prostate, bladder, testis, and penis.

Main Results:

  • Over 3,500 miRNA publications existed by August 2008, with an estimated 1,500 in 2008 alone.
  • miRNA expression studies confirm their role in cancer initiation and progression.
  • Urologic oncology had limited publications (22 prostate, 4 kidney, 3 bladder, 6 testis), indicating an early research stage.

Conclusions:

  • miRNAs show significant potential as diagnostic, prognostic, and predictive biomarkers in cancer.
  • The current data in urologic oncology is sparse and partly inconsistent, necessitating more research.
  • Understanding miRNA abnormalities could lead to novel diagnostic and therapeutic strategies for urological tumors.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.